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Summary
Objective: To compare the inﬂuence of concomitant heeled footwear when wearing a lateral wedged insole for medial compartment of osteo-
arthritis (OA) of the knee, between everyday walking shoes for outdoor use and socks or ﬂat footwear without a heel for indoor use.
Design: A total of 227 outpatients were prospectively randomized and treated with a neutral wedged insole inserted into shoes (placebo with
shoes; n¼ 45), a wedged insole inserted into shoes (inserted insole with shoes; n¼ 45), a sock-type ankle supporter with a wedged insole
when wearing socks or ﬂat footwear (inserted insole without shoes; n¼ 46), a subtalar strapped insole when wearing shoes (strapped insole
with shoes; n¼ 45), and the strapped insole with socks or ﬂat footwear (strapped insole without shoes; n¼ 46). The Lequesne index of knee
OA at week 12 was compared with the baseline in each treatment group.
Results: Twenty patients withdrew from the study, and the 207 patients who completed the 12-week study were evaluated. At the ﬁnal assess-
ment, participants wearing the inserted insole without shoes (P¼ 0.003), the strapped insole with shoes (P< 0.0001), and the strapped insole
without shoes (P< 0.0001) demonstrated signiﬁcantly improved Lequesne index scores in comparison with their baseline assessments. No
signiﬁcant differences were found in the placebo (P¼ 0.16) or the inserted insole with shoes (P¼ 0.2) groups.
Conclusion: Concomitant heeled footwear may decrease the efﬁcacy of an inserted lateral wedged insole. The optimal usage of a lateral
wedged insole for knee OA would be the combination with socks or ﬂat footwear without heels.
ª 2007 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
Key words: Osteoarthritis, Knee, Orthotic devices, Barefoot, Insole, Clinical study.Introduction
One of the ﬁrst conservative mechanical treatments for
patients with medial compartment osteoarthritis (OA) of the
knee was the use of a lateral wedged insole. However,
there were discrepancies in the clinical effects reported for
the use of the lateral wedged insoles between Japan and
Western countries.
In Japan, Sasaki et al.1 reported that during their 2.5-year
(mean) retrospective study, participants treated by a combi-
nation of lateral wedged insoles, mainly used without shoes
indoors, and taking indomethacine (600 mg/day) showed
a signiﬁcantly greater improvement in the Knee Rating
Scale (KRS) score measured from questions about pain
and walking ability, compared with participants treated
with indomethacine alone. Tohyama et al.2 also reported
that during their 9-year (mean) retrospective study, knee
OA patients treated with shoe-type heel wedges, used with-
out shoes indoors and taking analgesics, showed a signiﬁ-
cantly greater improvement in the KRS score, compared
with patients treated with analgesics alone.
Two prospective randomized and controlled follow-up
studies conducted in France, a 6-month and a 2-year study,
showed that subjects with knee OA had a decreased*Addresscorrespondenceand reprint requests to:YoshitakaToda,
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244non-steroidal anti-inﬂammatory drug (NSAID) intake
when they wore bilateral lateral wedged insoles inserted
into their ordinary shoes, but they did not report any
changes in pain, stiffness, or function as measured by
the Western Ontario and McMaster Universities’ (WO-
MAC) OA index3e5. From the results of a double-blind,
randomized crossover trial in 90 patients with knee OA
in the US, Baker et al.6 concluded that the effect of treat-
ment with an inserted lateral wedged insole for knee OA
was neither statistically signiﬁcant nor clinically important.
In the UK, Reilly et al.7 questioned the applicability of the
lateral wedged orthotic devices for knee OA reported in
Japanese studies to a more general population.
There are differences in both the life styles and the foot-
wears worn in Japan and Western countries. Most Japa-
nese wear footwear outdoors, but not inside their homes,
and the patients with knee OA use lateral wedged insoles
without shoes indoors. We hypothesized that a clue to the
solution of the discrepancies in the results from clinical stud-
ies of lateral wedged insoles conducted in Japan and West-
ern countries was the use of concomitant footwear when
using the insoles.
Therefore, this study was designed to compare the pain
improvement for 12 weeks using a clinical index in patients
treated with a neutrally wedged insoles used as a placebo
inserted in the regular shoes the patients used everyday
as walking shoes, a lateral wedged insole inserted in regu-
lar shoes, a sock-type ankle supporter with a lateral wedged
insole when wearing socks or ﬂat footwear without a heel,
a strapped insole when wearing regular shoes and the
strapped insole with socks or ﬂat footwear.
245Osteoarthritis and Cartilage Vol. 16, No. 2MethodsSTUDY DESIGNThis study was accomplished through a prospective eval-
uation of patients with medial compartment knee OA,
treated with either a neutrally wedged insole (used as a pla-
cebo) with shoes, a lateral wedged insole inserted in shoes,
a lateral wedged insole without shoes, a strapped lateral
wedged insole with shoes, and a strapped lateral wedged
insole without shoes. The setting for the study was an
Orthopedic Outpatient Clinic. The principal outcome results
considered were as follows:
 Algo-functional disability improvement using the Le-
quesne index8,9.
 Pain improvement using the Visual Analogue Scale
(VAS) for subjective knee pain.
 The number of days that participants needed the
NSAID.
The procedures employed were conducted in accordance
with the Declaration of Helsinki10.INCLUSION/EXCLUSION CRITERIATwo hundred and sixty-one new outpatients seen in our
Orthopedic Outpatients Clinic from July to December in
2006 were deﬁned as patients with medial compartment
OA knee, according to the American College of Rheumatol-
ogy criteria and a criterion stipulating a standing femoroti-
bial angle greater than 176 shown by X-ray (the mean
and standard deviation of the femorotibial angle in standing
radiographs in healthy Japanese adults is 174.6 1.7 and
a value exceeding 176 is considered to show varus
deformity)11,12.Subjects were defined as 
compartment OA 
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     Impossibility to quit previ
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with shoes group:
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The inserted in
without shoes g
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Are you  willing to participate in the
Yes: n=21 n=38 n=36
Fig. 1. Flowchart showing the patients whoExclusion criteria following the report by Maillerfert et al.3
were employed; a greater or similar reduction in the lateral
than the medial femorotibial joint space width (concomitance
with lateral kneeOA) shown on plain postero-anterior X-rays,
bilateral kneeOA, secondarykneeOA,hipOA,ankleOA, hal-
lux rigidus, valgusdeformity of themidfoot, or anyother symp-
tomatic deformity of the foot, advanced arthroplasty of the
hindfoot, any disease treated with insoles, previous ankle ar-
throdesis, tibial osteotomy, and any intra-articular corticoste-
roid or hyaluronan (HA) injection within 1 month. Additional
exclusioncriteria includedpatients usingcustomor functional
shoes for knee OA as their everyday walking shoes.
There were 11 patients who were not eligible, judged by
the exclusion criteria given above, and 13 patients refused
to participate in the study.
In the initial visit, the patients were asked about their drug
use history, i.e., use of an analgesic, NSAID and alternative
medication including glucosamine use within the previous
week. There were 171 patients who had a positive drug his-
tory of the 237 participants who were eligible for inclusion
(72.2%) in the study. It was required that these 171 patients
should discontinue the use of previous medications during
a 1-week washout period between the initial visit and the
baseline assessment. During the washout period, 10 of
these 171 patients (5.8%) could not quit their previous
medications.
After providing informed consent, 227 outpatients includ-
ing 27 males and 200 females with knee OA (mean age:
64.3, standard deviation: 9.0) were treated with an orthotic
device or the placebo for 12 weeks (Fig. 1).PROCEDURESAll participants were given a uniform NSAID (lornoxicam
4 mg twice daily) as an adjunctive therapy. In the course ofpatients with medial
knee: n=261 
: n=11
ous medications: n=10
ipants: n=227
The strapped insole
with shoes group:
n=45
n=41
sole
roup:
The strapped insole
without shoes group:
n=46
=5 Withdrawn: n=4 Withdrawn: n=2
n=44
 6-month follow-up study? 
n=35 n=40
were lost to follow-up during the trial.
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any painful conditions related to his/her knee OA, but the
participants were instructed to record how many days
they needed the NSAID in their diary.TREATMENT GROUPSFive types of orthotic devices were prepared:
1. A neutrally wedged insole for reducing foot odor used
as a placebo inserted in regular shoes (Odor Eater,
Kobayashi Pharmaceuticals, Osaka, Japan) . The pla-
cebo insole [Fig. 2(A)] was inserted in the regular
shoes the patients in this group wore as everyday
walking shoes for outdoor use (the placebo with
shoes).
2. A traditional shoe inserted insole (Wedge Heel Type,
Sanshinkousan Co. Ltd., Osaka, Japan) which had
a lateral sponge rubber heel wedge with an elevation
of 6.35 mm (tilt angle¼ 5). The inserted insole
[Fig. 2(B)] was inserted in shoes worn for outdoor
use (the inserted insole with shoes).
3. A sock-type ankle supporter with the lateral rubber
heel wedge insert sewn in. This insert was made of
the same material and had the same tilt angle as the
insert used for the above inserted insole, and it was in-
serted into the heel (Wedge heel supporter, Sanshin-
kosan Co. Ltd., Japan). This sock-type ankle supportPlacebo insole
Sock-type ankle support 
Inserted insole
Placebo with shoes
Inserted insole with shoes
Inserted insole without shoes  
A
B
C
Fig. 2. The construction of the ﬁve types of orthotic devices. The placebo
patient’s footprint. These ﬂat urethane sheets contain an active carbon to
adhesive tape, and a lateral rubber wedge with an elevation of 6.35 m
metatarsals and a lateral wedged insole with an elevation of 6.35 mm was
support band with adhesive tape and a urethane lateral wedge with an elev
around the ankle and subtalar joints. The ends were afﬁxed with adhesive
has ﬂat urethane sole[Fig. 2(C)] was employed for footwear for indoor use
when wearing socks or ﬂat footwear without any heel
height (the inserted insole without shoes).
4. A urethane wedge with an elevation of 12 mm (tilt
angle¼ 11.2) which was ﬁxed to an ankle sprain sup-
port, designed to ﬁt around the ankle and subtalar
joints (Sofra Wolfer OAR, Taketoraa Co. Ltd., Tokyo,
Japan). The ankle sprain support was made of 50%
polyester, 30% nylon, and 20% polyurethane, with
a 230% stretch rate. The strapped insole [Fig. 2(D)]
was used either in combination with socks or ﬂat foot-
wear indoors (the strapped insole without shoes) or the
patients’ everyday walking shoes for outdoor use (the
strapped insole with shoes).
5. Flat footwear [Fig. 2(E)] without any heel height
(Tento-Yobo Shoes, Taketora Co. Ltd., Tokyo,
Japan) was used when a participant had a life style
of wearing footwear indoors and was treated with the
inserted insole without shoes or the strapped insole
without shoes.
The 227 participants were randomly allocated into one of
following groups using the intervention noted: the placebo
with shoes group, the inserted insole with shoes group,
the inserted insole without shoes group, the strapped insole
with shoes group, or the strapped insole without shoes
group (Fig. 1). The randomization procedure for the alloca-
tion was a computer-generated block method using sealedStrapped insole 
Flat footwear
Strapped insole with shoes 
Strapped insole
without shoes  
Inserted insole under flat
footwear without shoes 
Strapped insole under flat
footwear without shoes
E
D
insole (A) was made by cutting a ﬂat urethane sheet to match each
reduce foot odor. The inserted insole (B) consisted of a nylon seat,
m. The sock-type ankle supporter (C) extended from the to the
sewn into the heel. The strapped insoles (D) consisted of an ankle
ation of 12 mm. The ends of the supporter were twisted in a ﬁgure 8
tape at the posterior ankle and subtalar joints. The ﬂat footwear (E)
s with no heel.
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generated treatment allocations within sealed opaque enve-
lopes in a series of blocks of 10. Once a patient had entered
the trial in the baseline assessment, an envelope was
opened and the patient was then offered the allocated inter-
vention regimen.
Based on the results of our previous study, in which we
investigated the optimal duration of daily wear for a strapped
insole, participants in the inserted and strapped insole with-
out shoes groups were instructed to use the insole in their
homes between 5 and 10 h each day13. The participants
in the placebo, inserted and strapped insole with shoes
groups were advised to use the allocated insole whenever
wearing shoes, between 5 and 10 h each day.
The device was checked every 2 weeks and proper use
of the insole was conﬁrmed by the wear of the material
during that inspection.CHARACTERISTICS OF THE PARTICIPANTSThe age, disease duration, gender, height, weight, Kellg-
ren and Lawrence grade (KeL grade) for radiographic
severity14 and femorotibial angle assessed in standing ra-
diographs were evaluated at the baseline. Disease duration
was based upon the patients’ recollection of the onset of
knee pain. Height was measured to the nearest 1 cm using
a stadiometer. Weight was measured to the nearest 0.1 kg
with subjects standing erect, wearing underwear and robes
without shoes. Body mass index (BMI) was calculated from
weight and height as weight (kg)/height2 (m).OUTCOME MEASURESThis study was accomplished through an intention to treat
analysis. In the course of the 12-week study, every partici-
pant could propose quitting the allocated orthotic device for
any discomfort that they did not feel before the use of the
device. The reasons given for discontinuing the use of
the allocated device were recorded for each group and
the Lequesne index and the VAS at the last observation
of material wear were carried forward.
A research nurse who was blind to the objectives of the
study asked the participants to assess the Lequesne index
and VAS for subjective knee pain at the baseline and
12-week assessments. The Lequesne index and VAS at
the 12-week assessment were compared with the baseline
recordings for each group. The analyses were repeated for
the subset of women only, as knee OA biomechanics and
footwear may differ between the sexes.
At the ﬁnal assessment, the participants were asked how
many days they needed the NSAID because of a painful
condition related to his/her knee OA, based on their diary
during the 12-week study. The number of days they needed
the NSAID was compared between the ﬁve groups.
After receiving treatment for 12 weeks, all of the patients
were asked whether they would be willing to participate in
the 6-month follow-up study to evaluate the tolerability of
the allocated orthotic device.STATISTICAL ANALYSESThe characteristics of the participants (age, disease dura-
tion, BMI, and femorotibial angle), VAS and Lequesne index
at the baseline assessment, and the number of days the
participants needed the NSAID between the groups were
compared using one-way analysis of variance (ANOVA).The radiographic grade, sex and the number of subjects
willing to participate in the 6-month follow-up study were
compared between the groups using the chi-squared test.
Applying a Bonferroni adjustment for the use of the multiple
ANOVA and the chi-squared test, 10 comparisons were
conducted for the ﬁve groups, and we deﬁned statistical
signiﬁcance at P less than 0.005 (0.05/10).
The paired t test was used to assess the statistically sig-
niﬁcant differences in the Lequesne index and the VAS be-
tween the baseline and the 12-week assessments in each
group. Statistical signiﬁcance levels for the paired t test
were considered to be P< 0.05.ResultsCHARACTERISTICS OF THE PARTICIPANTSTwenty of the 227 subjects (8.8%) did not complete the
12-week study, including seven in the placebo with shoes
group, two in the inserted insole with shoes group, ﬁve in
the inserted insole without shoes group, four in the strapped
insole with shoes group, and two in the strapped insole
without shoes group.
Of the 207 who completed the study, there were 38 par-
ticipants in the placebo with shoes group, 43 in the inserted
insole with shoes group, 41 in the inserted insole without
shoes group, 41 in the strapped insole with shoes group,
and 44 in the strapped insole without shoes group
(Fig. 1). At the baseline assessment, there were no signiﬁ-
cant differences between any two of the ﬁve groups in age,
disease duration, BMI, femorotibial angle, Lequesne index,
VAS or distributions of gender, and KeL grade (P> 0.005)
(Table I). Four of the 41 subjects (9.8%) in the inserted in-
sole without shoes group and ﬁve of the 44 (11.4%) sub-
jects in the strapped insole without shoes groups had
a life style that included wearing footwear indoors. These
nine subjects were instructed to use the allocated insole
with the ﬂat footwear indoors.
From observations of material wear, we judged that each
participant used the allocated device as instructed.LEQUESNE INDEXThe mean values and standard deviations for changes in
the Lequesne index at the ﬁnal assessment, compared with
the baseline assessment were, 0.66 4.4 in the placebo
with shoes group, 0.44 3.7 in the inserted insole with
shoes group, 1.7 4.2 in the inserted insole without shoes
group, 3.0 4.8 in the strapped insole with shoes group,
and 3.9 5.0 in the strapped insole without shoes group.
Participants wearing the inserted insole without shoes
(P¼ 0.003), the strapped insole with shoes (P< 0.0001)
and the strapped insole without shoes (P< 0.0001) demon-
strated signiﬁcantly improved Lequesne index values in com-
parison with their baseline assessments. These signiﬁcant
differences were not found in the groups with the placebo
with shoes (P¼ 0.16) or the inserted insole with shoes
(P¼ 0.2) (Table II).VAS FOR SUBJECTIVE KNEE PAINCompared with the baseline assessments, the VAS for
subjective knee pain in the strapped insole with shoes
(6.3 21.1%) and the strapped insole without shoes
groups at week 12 (8.7 21.7%) was signiﬁcantly im-
proved (P¼ 0.009 and P¼ 0.002, respectively). There
Table I
Characteristics of the participants who completed the 12-week study (n¼ 207)
Age
(years)
Disease
duration
(years)
Body mass
index
(kg/m2)
Femorotibial
angle
(degree)
Lequesne
index
(score)
VAS (%) Sex
(no. of cases)
Radiographic
grade
(no. of cases)
I. Placebo with shoes (n¼ 38)
Mean (SD) 64.6 (9.8) 3.4 (4.8) 24.6 (3.1) 180.3 (5.3) 9.0 (4.8) 44.3 (19.0) Men (6) II (23)
Median 66 1.0 24.3 179.5 9.0 50.0 Women (32) III (9)
95% CI 61.2e68.1 1.8e5.1 23.5e25.7 178.5e182.1 7.3e10.7 38.4e50.3 IV (6)
II. Inserted insole with shoes (n¼ 43)
Mean (SD) 66.1 (8.6) 4.3 (5.2) 24.7 (2.9) 180.4 (4.5) 9.9 (4.8) 39.2 (19.9) Men (5) II (27)
Median 67 2.3 24.2 180.0 9.0 39.5 Women (38) III (13)
95% CI 63.5e68.8 2.7e5.9 23.8e25.6 179.0e181.8 8.4e11.3 33.0e45.4 IV (3)
III. Inserted insole without shoes (n¼ 41)
Mean (SD) 65.2 (8.6) 4.2 (5.3) 24.8 (2.9) 180.5 (4.2) 10.4 (5.0) 45.5 (21.2) Men (5) II (25)
Median 67 1.5 24.2 179.0 9.0 47.0 Women (36) III (13)
95% CI 62.5e67.9 2.5e5.9 23.8e25.7 179.1e181.9 8.8e12.0 38.8e52.2 IV (3)
IV. Strapped insole with shoes (n¼ 41)
Mean (SD) 62.9 (7.5) 4.7 (5.2) 25.7 (3.5) 181.7 (4.9) 9.8 (5.4) 38.5 (20.5) Men (3) II (28)
Median 63 3.0 26.1 181.0 10 40 Women (38) I (8)
95% CI 60.4e65.4 2.9e6.4 24.5e26.8 180.1e183.3 8.0e11.6 31.7e45.4 IV (5)
V. Strapped insole without shoes (n¼ 44)
Mean (SD) 64.0 (9.6) 4.6 (6.0) 25.2 (3.6) 181.6 (5.1) 9.9 (5.4) 38.1 (19.2) Men (5) II (30)
Median 65.5 1.8 25.1 180.5 10 39.5 Women (39) I (9)
95% CI 60.9e67.0 2.7e6.5 24.1e26.4 179.9e183.2 8.2e11.6 31.9e44.2 IV (5)
P values
between
thegrades
I and II 0.49 0.42 0.84 0.92 0.49 0.33 0.59 0.42
I and III 0.72 0.44 0.85 0.86 0.25 0.71 0.65 0.43
I and IV 0.65 0.15 0.34 0.18 0.42 0.24 0.24 0.77
I and V 0.99 0.16 0.66 0.21 0.39 0.19 0.56 0.75
II and III 0.73 0.98 0.99 0.94 0.63 0.17 0.94 0.99
II and IV 0.24 0.50 0.23 0.19 0.90 0.81 0.50 0.44
II and V 0.46 0.54 0.50 0.22 0.86 0.72 1.0 0.40
III and IV 0.41 0.49 0.24 0.22 0.72 0.12 0.48 0.42
III and V 0.70 0.52 0.52 0.26 0.75 0.089 0.91 0.42
IV and V 0.65 0.95 0.58 0.91 0.97 0.92 0.52 0.99
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VAS at the 12-week and baseline assessments in the
groups with the placebo with shoes, the inserted insole
with shoes and the inserted insole without shoes
(P¼ 0.13, P¼ 0.41 and P¼ 0.31, respectively) (Table II).WOMEN SUBSET ANALYSISIn the subset of 183 women who completed the 12-week
study, participants wearing the strapped insole with shoes
(n¼ 38) and the strapped insole without shoes (n¼ 39)
demonstrated both Lequesne index scores and VAS that
were signiﬁcantly improved, compared with their baseline
assessments. These signiﬁcant differences were not found
in the placebo (n¼ 32) or the inserted insole with shoes
group (n¼ 38). In the inserted insole without shoes group
(n¼ 36), there was a signiﬁcant difference in the Lequesne
index score, but not in the VAS (Table III). The distribution
of the statistical signiﬁcances was the same as it was in
the assessments for both male and female subjects.NUMBER OF DAYS SUBJECTS NEEDED THE NSAIDConcerning the number of days the participants needed
the NSAID during the 12-week study period, there were sig-
niﬁcant differences demonstrated between the groups with
placebo with shoes (17.4 10.9 days) and the inserted in-
sole with shoes (12.5 6.9 days) (P¼ 0.004), between
the groups with the placebo with shoes and the insertedinsole without shoes (11.8 7.1 days) (P¼ 0.001), between
the groups with the placebo with shoes and the strapped
insole with shoes (10.7 6.3 days) (P< 0.0001), and be-
tween the groups with the placebo with shoes and the strap-
ped insole without shoes (11.2 6.5 days) (P< 0.0001)
(Fig. 3).
There were no signiﬁcant differences between any other
two groups in the number of days the participants needed
the NSAID (P> 0.005).OBSERVATIONS OF DROP-OUTSConcerning the reasons for withdrawal, 13 of the 20 par-
ticipants (65%) proposed quitting the allocated orthotic de-
vice, four withdrew due to family commitments, two
moved, and one received total knee arthroplasty. The rea-
son given for proposing to quit the placebo with shoes
was its ineffectiveness (n¼ 4). One subject cited foot sole
pain as the reason for discontinuing the use of the inserted
insole with shoes. The reasons for discontinuing the use of
the inserted insole without shoes were sweating of the foot
(n¼ 2) and foot sole pain (n¼ 1). The reasons for discontin-
uing the use of the strapped insole with shoes was foot pain
due to the foot being cramped inside their shoes (n¼ 2) and
popliteal pain (n¼ 1). One subject cited popliteal pain as the
reason for discontinuing the use of the strapped insole with-
out shoes (Table IV).
Treatments for the 13 participants who indicated that they
wanted to quit the allocated orthotic device were changed
Table II
Comparison of the Lequesne index and VAS between baseline and 12 weeks (n¼ 207)
Lequesne index VAS (%)
12 weeks Comparison with
the baseline
P values between
the baseline and
12 weeks
12 weeks Comparison with
the baseline
P values between
the baseline and
12 weeks
Placebo with shoes (n¼ 38)
Mean (SD) 8.1 (5.0) 0.66 (4.4) 46.5 (15.3) 2.6 (10.0)
Median 8.0 0.5 0.16 50.0 0 0.13
95% CI 6.4e9.7 2.1e0.78 41.4e51.5 0.75e5.9
Inserted insole with shoes (n¼ 43)
Mean (SD) 9.1 (5.3) 0.44 (3.7) 41.9 (23.1) 2.3 (18.5)
Median 8.0 1.0 0.20 46.0 0 0.41
95% CI 7.5e10.7 1.6e0.7 34.8e49.0 3.4e8.0
Inserted insole without shoes (n¼ 41)
Mean (SD) 8.4 (5.8) 1.7 (4.2) 42.0 (25.4) 3.5 (21.7)
Median 7.0 1.0 0.003* 44.0 1.0 0.31
95% CI 6.6e10.2 3e0.36 34.0e50.1 10.3e3.4
Strapped insole with shoes (n¼ 41)
Mean (SD) 6.8 (5.1) 3.0 (4.8) 29.4 (19.4) 6.3 (21.1)
Median 6.0 2.0 P< 0.0001* 24.0 4.0 0.004*
95% CI 5.1e8.5 4.6e1.4 23.0e35.9 13.3e0.78
Strapped insole without shoes (n¼ 44)
Mean (SD) 6.2 (5.3) 3.9 (5.0) 27.4 (20.0) 8.7 (21.7)
Median 5.0 3.0 P< 0.0001* 22.0 8.0 0.002*
95% CI 4.5e7.9 5.5e2.3 20.9e33.8 15.7e1.7
*P< 0. 05.
249Osteoarthritis and Cartilage Vol. 16, No. 2from the orthotic device to standard conservative treat-
ments, including an intra-articular injection with HA. The
four subjects who withdrew due to family commitments
were lost for the follow-up study. We provided a letter of
introduction to two subjects who moved and one who
received total knee arthroplasty, so they could change
hospitals.Table I
Comparison of the outcomes for women subset
Lequesne index
12 weeks Comparison with
the baseline
P value betwe
the baseline a
12 weeks
Placebo with shoes (n¼ 32)
Mean (SD) 8.8 (5.1) 0.62 (4.7)
Median 8.0 0 0.22
95% CI 6.9e10.8 2.4e1.2
Inserted insole with shoes (n¼ 38)
Mean (SD) 9.4 (5.4) 0.29 (3.9)
Median 8.5 0.5 0.34
95% CI 7.6e11.1 1.6e1.0
Inserted insole without shoes (n¼ 36)
Mean (SD) 8.7 (5.8) 1.8 (4.4)
Median 7.0 1.0 0.06
95% CI 6.7e10.7 3.3e0.25
Strapped insole with shoes (n¼ 38)
Mean (SD) 6.9 (5.3) 3.2 (4.9)
Median 5.5 2.5 P< 0.0001*
95% CI 5.1e8.8 4.9e1.5
Strapped insole without shoes (n¼ 39)
Mean (SD) 6.1 (5.4) 4.0 (5.2)
Median 5.0 3.5 P< 0.0001*
95% CI 4.2e7.9 5.8e2.2
*P< 0.05.The analyses were repeated, adding the 20 drop-out
cases to the 207 who completed the study using the Last Ob-
servation Carried Forward method in order to handle the
missing data (n¼ 227). Compared with the baseline assess-
ments, the Lequesne index was signiﬁcantly improved in the
inserted insole without shoes group (P¼ 0.006), the strap-
ped insole with shoes group (P< 0.0001), and the strappedII
between baseline and 12 weeks (n¼ 183)
VAS (%)
en
nd
12 weeks Comparison with
the baseline
P value between
the baseline and
12 weeks
47.8 (16.2) 2.9 (9.6)
50.0 0 0.11
41.7e53.9 0.71e6.6
42.1 (23.4) 3.7 (18.6)
45.5 2 0.23
34.4e49.8 2.4e9.9
42.1 (26.2) 3.7 (22.9)
42.5 0.5 0.34
33.2e50.9 11.5e4.1
29.5 (19.0) 7.4 (21.4)
24.5 5.5 0.004*
22.9e36.1 14.8e0.70
27.2 (19.2) 9.4 (21.9)
22.0 7.5 0.002*
20.6e33.8 17.1e1.8
Fig. 3. Comparison of the number of days the subjects needed the NSAID between the ﬁve groups.
250 Y. Toda and N. Tsukimura: Footwear and insole for knee OAinsole without shoes group (P< 0.0001), but not in the pla-
cebo with shoes group (P¼ 0.51) or the inserted insole
with shoes group (P¼ 0.33). The VAS was signiﬁcantly im-
proved in the strapped insole with shoes group (P¼ 0.006)
and the strapped insole without shoes group (P< 0.0001),
but not in the placebo with shoes group (P¼ 0.067), the in-
serted insole with shoes group (P¼ 0.37) or the inserted in-
sole without shoes group (P¼ 0.64). The distribution of the
statistical signiﬁcances was the same as it was in theTable I
The outcomes at the baseline and last ass
The reason
for withdrawal
The last
assessment
(weeks)
L
Basel
Placebo with shoes
Case 1 Inefﬁcacy 2 6 poin
2 Inefﬁcacy 2 7
3 Inefﬁcacy 2 9
4 Inefﬁcacy 2 10
5 Arthroplasty 10 13
6 Having moved 8 17
7 Household commitments 6 18
Inserted insole with shoes
Case 1 Foot sole pain 2 2 poin
2 Household commitments 6 14
Inserted insole with shoes
Case 1 Foot sole pain 2 5 poin
2 Foot sole pain 2 5
3 Sweating in the feet 2 6
4 Sweating in the feet 4 11
5 Having moved 6 16
Strapped insole with shoes
Case 1 Feeling cramped inside shoes 2 2 poin
2 Feeling cramped inside shoes 2 6
3 Popliteal pain 4 8
4 Household commitments 6 15
Strapped insole without shoes
Case 1 Popliteal pain 2 4 poin
2 Household commitments 8 16assessments that only included subjects who completed
the study.WILLING TO PARTICIPATE IN THE 6-MONTH STUDYThirty-seven of the 207 subjects (17.9%) who completed
the 12-week study, including 17 in the placebo with shoes
group, ﬁve in the inserted insole with shoes group, ﬁve in
the inserted insole without shoes group, six in the strappedV
essments for drop-out cases (n¼ 20)
equesne index (points) VAS (%)
ine Last Change Baseline Last Change
ts 9 3 40% 52 12
9 2 45 63 18
11 2 50 55 5
20 10 49 61 12
16 3 40 46 6
17 0 50 32 18
17 1 48 45 3
ts 9 7 28% 57 29
13 1 65 49 16
ts 9 4 20% 63 43
8 3 50 63 13
6 0 44 48 4
9 2 24 33 9
14 2 31 35 4
ts 4 2 50% 59 9
5 1 50 45 5
9 1 75 67 8
9 6 78 61 17
ts 7 3 27% 50 23
10 6 50 24 26
251Osteoarthritis and Cartilage Vol. 16, No. 2insole with shoes group, and four in the strapped insole
without shoes group, did not want to wear their respective
insoles continuously (Fig. 1).
The frequency of participants who did not want to wear
their respective insoles continuously was signiﬁcantly
higher in the placebo with shoes group, compared with
the other groups (P< 0.0001).Discussion
In this study, participants wearing the inserted insole with-
out shoes demonstrated signiﬁcantly improved Lequesne in-
dex scores in comparison with their baseline assessments.
These signiﬁcant differences were not found in the placebo
with shoes group. These results concur with the reports by
Sasaki and Tohyama et al.1,2, in which patients treated
with inserted insoles mainly used without shoes indoors
and an analgesia showed a signiﬁcantly greater improve-
ment than participants treated with an analgesia alone.
Although neither the VAS nor Lequesne index was signif-
icantly reduced at the 12-week assessment compared with
the baseline assessment in the inserted insole with shoes
group, there was a signiﬁcant difference in the number of
days the subjects needed the NSAID demonstrated be-
tween the placebo with shoes and inserted insole with
shoes groups in the current study. These results corre-
sponded to the results shown by Maillerfert and Pham
et al.3,4, which showed that subjects with knee OA demon-
strated a decreased NSAID intake when they wore bilateral
lateral wedged insoles inserted into their ordinary shoes,
but no change in the WOMAC OA index.
One standard parameter assessed as a marker of knee
loading is the external knee adduction moment, a varus mo-
ment on the knee that reﬂects the magnitude of medial com-
partment joint loading15. Kerrigan et al.15 reported that the
insertion of lateral wedged insoles into regular shoes can
induce signiﬁcant decrease in knee varus moment (by up
to 5e7%) in subjects with medial compartment knee OA.
They also showed that even women’s shoes with
a 1.5 inch heel (moderate high-heeled shoes) signiﬁcantly
increased knee varus moment compared with walking
barefoot16.
Shakoor et al.17 reported that peak joint loads at the
knees signiﬁcantly decreased during barefoot walking,
with an 11.9% reduction noted in the knee varus moment
compared with when wearing commercial walking shoes.
It was of interest that they observed relative load reductions
of nearly 12% at the knee merely by walking barefoot, which
appears to be substantially greater than the experience with
lateral wedged inserts by Kerrigan et al.15. Shakoor et al.17
mentioned that most commercial walking shoes have a par-
tial lift at the heel, and thus, the complete lack of a ‘‘heel’’
during barefoot walking may be effective for reducing the
peak torque at the knee. Kuroyanagi et al.18 showed that
the varus moment was reduced 13.1% due to wearing the
lateral wedged insole with elastic strapping of the subtalar
joint (the strapped insole) added to a bare foot, compared
with walking barefoot for 37 patients with knee OA. Clinical
results from a study on the use of strapped insole were also
reported by Toda et al.19
According to the results from these reports15e18, we con-
sidered that the differences in the varus moments between
wearing the strapping insole added to a bare foot and wear-
ing moderate high-heeled shoes alone might be greater
than the differences shown between wearing moderate
high-heeled shoes alone and when inserting wedges intothe shoes. These biomechanical effects on the varus mo-
ment may reﬂect the clinical efﬁcacy of treatments for
knee OA using lateral wedged insoles. From these results,
we concluded that the discrepancies in the reported clinical
effects of inserted insoles between Japan and Western
countries will depend on the differences of concomitant
heeled footwear when using inserted insoles.
Yasuda and Sasaki20 speculated that the beneﬁcial effect
of the inserted insole was due to the reduction in the medial
knee joint surface loading with a concurrent reduction in lat-
eral tensile forces, even though the device failed to correct
the femorotibial angle in patients with varus deformity with
medial compartment OA knee. In research conducted on al-
ternatives to correct the femorotibial angle by a lateral
wedged insole, this limitation of the inserted insoles was ad-
dressed through the development of a novel lateral wedged
insole with elastic ﬁxation of the subtalar joint (the strapped
insole)19. The realignment produced by the strapped insole
led to the conclusion that an insole with elastic ﬁxation ob-
tained with tension by a subtalar and ankle joint band leads
to valgus angulation of the talus, resulting in correction of
the femorotibial angle in patients with varus deformity
knee OA19.
In our prospective randomized controlled studies, a 6-
month study and a 2-year follow-up study, participants
wearing the subtalar strapped insole demonstrated signiﬁ-
cantly decreased femorotibial angles, and signiﬁcantly im-
proved Lequesne index values in comparison with their
baseline assessments21,22. These signiﬁcant differences
were not found in the groups with the inserted insoles.
In the current study, even when worn with shoes, the
strapped insole signiﬁcantly improved both the VAS and Le-
quesne index values obtained at the 12-week assessment,
compared with the baseline assessment. However, the dis-
advantage associated with the strapped insole concomitant
with everyday walking shoes was that some patients felt
foot pain due to feeling cramped inside their shoes in order
to accommodate the thickness of the supporter and ure-
thane insole. This disadvantage was demonstrated in the
current study and also in previous studies21,22.
In the current study, signiﬁcantly improved VAS and Le-
quesne index values were demonstrated for the strapped in-
sole without shoes group at week 12, in comparison with the
baseline assessment. The number of days the subjects
needed theNSAIDwassigniﬁcantly less in thestrapped insole
without shoesgroup than that in theplacebowith shoesgroup.
Considering these results, we concluded that when wear-
ing socks or ﬂat footwear without heels, the strapped insole
would be more effective than an inserted insole with shoes
for patients with knee OA. Although the change in life style
will be difﬁcult we would like to recommend taking off shoes
with heels and walking, while wearing socks or ﬂat footwear
without heels with a strapped insole at home for Western
people with knee OA.
The current study was limited in that the methodology
employed for the conﬁrmation of material wear was incom-
plete. We detected patients who did not use the insoles
from the observations during the inspections of the material
wear. When the participants in the strapped insole with
shoes group used the insoles inside without shoes at
home, we could recognize this, as the parts of the support
that touched the ﬂoor were more soiled than those only
used with shoes. However, it will be necessary to consider
other reliability measures, including material testing, in
a future study.
Future studies should assess the footwear heel height,
which may be exaggerated, and therefore minimize the
252 Y. Toda and N. Tsukimura: Footwear and insole for knee OAeffect of the lateral wedge. Kerigan et al.23 showed that
men’s sneakers and dress shoes with an average 0.5 inch
heel height did not exaggerate knee joints’ torque, in men,
compared with walking bare foot, although they also
showed that women’s shoes with a 1.5 inch heel height sig-
niﬁcantly increased the torque16. Thus, the actual lower limit
for exaggerated footwear heel height may be between 0.5
and 1.5 inch.
The observation period in this study was only 12 weeks.
One of the reasons we employed this length for the obser-
vation period was that the compliance of patients in the pla-
cebo group was considered to decrease in a long-term
study, as the frequency of participants who were not willing
to participate in the 6-month study was signiﬁcantly higher
in the placebo with shoes group than in the other groups.
However, it will be necessary to continue the follow-up pe-
riod in order to assess treatment efﬁcacy over an observa-
tion period longer than the 12-week period, and we consider
that it will be necessary to employ a control group different
from the placebo group used in this study.
Concerning the different material employed for the in-
serted and strapped insoles, we assessed the lower ex-
tremity valgus realignment, symptomatic relief and
adverse effects in patients treated with the insoles com-
posed of sponge rubber or urethane with subtalar strapping
in a previous study24. The lateral wedge in combination with
subtalar strapping had a more natural form-ﬁt to the sole
than the insole insert alone. Although an ordinary inserted
lateral wedged insole had been made of sponge rubber,
we concluded that the sponge rubber is too hard to use
for the insole with subtalar strapping.
In the current study, a ready-made, low cost and readily
available insole was used as the placebo insole. The mate-
rial employed for the neutral wedged insole used as the pla-
cebo was therefore not the same material employed for the
inserted lateral wedge with shoes, although the two devices
were formed into a nearly identical shape. In order to func-
tion as a true control, the neutral wedged insole should
have been comprised of the same material as the lateral
wedge, and this issue will be addressed in a future study.
Furthermore, there was no provision for arch support in
the midfoot of the inserted lateral wedge with shoes, and
therefore it was possible that a ﬂexible low arched foot
type would pronate in the midfoot as a result of the lateral
wedging as opposed to translating the effect of the wedge
to the knee. A future study should be conducted to evaluate
the use of the inserted lateral wedge combined with arch
support.
The prevalence of OA knee in our society is increasing
due to the escalating proportion of elderly citizens. A con-
servative therapy such as use of an insole that provides
a low cost, effective compliment or alternative to surgical
treatment would be a very useful adjunct to the care of
these patients and of beneﬁt to the health care economy.References
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